The biopharma world is here. Get the industry’s most comprehensive daily news reports at https://xitter.cf/t.co/qpcDlbaOSx
Global
Joined August 2015
- Tweets51K
- Following80
- Followers32.7K
- Likes4.5K
Pharma is bracing for tougher Treasury scrutiny of China deals, with draft outbound investment rules expected Thursday.
endpoints.news/treasury-expe…
AI slop, agents everywhere and a biosecurity gap: @AndrewE_Dunn's five takeaways from our third AI Day.
endpoints.news/5-takeaways-f…
Roivant's Lisraya succeeded in two pivotal trials in a rare eye condition, setting up a 2027 filing.
endpoints.news/roivants-auto…
It doesn’t really matter what AI makes if there isn’t a proper system to put novel medicines into use, argued Kyunghyun Cho, CEO of Ortet, during Endpoints’ AI Day in New York City. “AI can engineer molecules, but it cannot engineer medicine,” he said. Hear the rest of his on-stage “hot take”: youtu.be/IYW8nWZXvqA?si=HiIW…
Drug launch prices are outpacing their worth, with only one of 26 new drugs meeting ICER's value benchmark.
endpoints.news/new-icer-repo…
Ahead of its obesity launch, Lilly's retatrutide is creeping closer to market for sleep apnea.
endpoints.news/lillys-retatr…
GSK's Hibsago won FDA approval as a potential functional cure for hepatitis B, but a black box warning could limit its appeal.
endpoints.news/gsk-gets-fda-…
Biopharma sentiment turned positive for the first time since the post-pandemic downturn, driven by dealmaking, our latest survey found. Read the report: endpoints.news/biopharma-sen…
Exclusive: Astellas struck a deal with AI Proteins that could top $400M, betting on the startup’s AI-designed miniproteins. endpoints.news/exclusive-ast…
Endpoints News retweeted
Biopharma is finally in a good mood.
Our Biopharma Sentiment Index hit 105 in Q3, its first reading above neutral. A year ago it was 76.
The lift came from rising assessments of current conditions for the industry. The future that insiders kept predicting has arrived 1/
Our Health Tech Day agenda is out, plus OpenAI’s Nate Gross joins us to talk about the company’s health ambitions. Early bird ends Friday. Reserve your spot: events.endpoints.news/health…
Antheia won a conditional $80M Defense Department loan to make generic drug ingredients in the US, as Trump pushes onshoring. endpoints.news/antheia-gets-…
Rapport’s oral drug licensed from J&J cleared a Phase 2 bipolar mania study, paving the way for registrational trials next year. endpoints.news/rapport-says-…
ESMO first look: Zai Lab’s chemo-free combo posted an 80% response rate in small cell lung cancer, as GSK and Merck also detailed wins and setbacks. endpoints.news/esmo26-regula…
Exclusive: Sanofi tapped ScionxBio to screen its mRNA candidates, the startup’s first deal since splitting from Eleven Therapeutics. endpoints.news/sanofi-taps-n…
Merck KGaA agreed to buy Silence Therapeutics for $1.3B, adding an siRNA drug headed into Phase 3 for a rare blood cancer. endpoints.news/merck-kgaa-wi…
Veradermics’ oral twist on Rogaine won again in a late-stage trial, meeting all its goals in men with male pattern hair loss. endpoints.news/veradermics-o…
After an FDA rejection, Disc Medicine’s drug for a rare disease that makes sun exposure painful hit all endpoints in Phase 3. endpoints.news/disc-medicine…
